Through the detection of serum FADS2 levels in different populations, our study found that FADS2 was significantly higher in NAFLD patients with CAD than those with NAFLD alone and healthy people, further proving the important role of FADS2 in NAFLD complicated CAD. Here, FADS2 is linked to metabolic dysfunction-associated steatotic liver disease.